Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02119650
Title Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors Incyte Corporation
Indications
Therapies
Age Groups: adult
Covered Countries USA

Facility Status City State Zip Country Details
Phoenix Arizona United States Details
Fayetteville Arkansas United States Details
Fresno California United States Details
La Jolla California United States Details
San Diego California United States Details
San Francisco California United States Details
Lone Tree Colorado United States Details
Norwich Connecticut United States Details
Southington Connecticut United States Details
Augusta Georgia United States Details
Joliet Illinois United States Details
Indianapolis Indiana United States Details
Lafayette Indiana United States Details
Kansas City Kansas United States Details
Detroit Michigan United States Details
Saint Louis Missouri United States Details
Reno Nevada United States Details
Lebanon New Hampshire United States Details
Mount Kisco New York United States Details
New York New York United States Details
Winston-Salem North Carolina United States Details
Canton Ohio United States Details
Portland Oregon United States Details
Chattanooga Tennessee United States Details
Knoxville Tennessee United States Details
Memphis Tennessee United States Details
Ogden Utah United States Details
Leesburg Virginia United States Details
Kennewick Washington United States Details
Seattle Washington United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field